# PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials

Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission to develop next-generation neuropsychiatric treatments. CYB003, a deuterated psilocin candidate, has received Breakthrough Therapy Designation, and early data show 100% response and 71% remission rates after two 16 mg doses. Cybin expects to launch the EMBRACE Phase 3 trial and complete its Phase 2 GAD study by mid-2025.

 To view the full press release, visit https://ibn.fm/KWrAP

 About Cybin Inc.

 Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

 NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

 About PsychedelicNewsWire

 PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.PsychedelicNewsWire.com

 Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

 PsychedelicNewsWireAustin, Texaswww.PsychedelicNewsWire.com512.354.7000 OfficeEditor@PsychedelicNewsWire.com

 PsychedelicNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/pnw/psychedelicnewsbreaks-cybin-inc-nyse-american-cybn-neo-cybn-applauds-fda-support-for-psychedelic-therapeutics-advances-phase-3-trials/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cybin-receives-fda-support-for-accelerated-development-of-psychedelic-therapeutics/2e22ba341958a25813b25ab7d82f028b) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1kr56gx/cybin_receives_fda_support_for_accelerated/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/20/loft5A4B.webp)